Viral Filtration of Plasma-Derived Human IgG: A Case Study Using Viresolve NFP

Published on: 
, , ,
BioPharm International, BioPharm International-11-01-2004, Volume 17, Issue 11

Human plasma provides a rich source of therapeutic medicines, including gamma globulins, coagulation factors, albumin, alpha anti-trypsin, and others. In 2001, sales of immuno gamma-globulin (IgG) were estimated at $2 billion with a production rate of 50 metric tons for the year.1 A number of new therapeutic products have recently been introduced including Gammimune from Bayer, RhoPhylac from ZLB Behring, and Octagam from Octapharma.

Human plasma provides a rich source of therapeutic medicines, including gamma globulins, coagulation factors, albumin, alpha anti-trypsin, and others. In 2001, sales of immuno gamma-globulin (IgG) were estimated at $2 billion with a production rate of 50 metric tons for the year.1 A number of new therapeutic products have recently been introduced including Gammimune from Bayer, RhoPhylac from ZLB Behring, and Octagam from Octapharma. Hyperimmunes (IgGs with high levels of antibodies targeted at a specific antigen such as a virus) are also under development for biodefense applications such as anthrax or smallpox. These can find usefulness as either therapeutics or preventative measures.

In the past, contamination of source plasma by enveloped viruses (HIV, HCV) has led to the contamination of plasma products and patient infection.2,3 In response, the industry adopted a multi-layered virus safety strategy that includes source plasma control (donor screening, plasma testing), product manufacturing (plasma pooling, clearance steps in plasma product manufacturing, cGMP), product testing, and pharmacovigilence (patient monitoring, recalls). The enveloped virus problem has been addressed by the adoption of virus clearance technologies such as solvent detergent, heat, low pH, caprylate, chromatography, and large virus filtration. Regulatory authorities have issued regulations describing requirements for marketing approval.4,5

Current plasma product safety concerns are focused on the smaller non-enveloped viruses (HAV, B9) and new agents (TSE, WNV, SARS). These small, non-enveloped viruses can be more difficult to inactivate or remove.6 The solvent detergent method, which is effective in preventing enveloped virus replication (through dissolution of their lipid envelope coating), is ineffective at inactivating non-enveloped viruses. The severe treatment conditions required for some non-enveloped virus inactivation (for example, 100B°C for PPV) can lead to significant product losses and potential formation of neo-antigens.

Figure 1. Magnified Image of Viresolve NFP Membrane


Virus filtration is a useful clearance method for non-enveloped viruses.


Filters are inert and do not degrade the product or add any foreign substances requiring removal. They are also capable of providing high product yield, can be validated using scaledown models and in-process integrity tests, and can be conveniently integrated into manufacturing processes.

Virus filtration is a well-established unit operation in biopharmaceutical processes and has been implemented in a number of approved products dating back to the mid 1990s. Mononine, a Factor IX product developed by Armour Pharmaceutical Company, was approved in 1992 using an ultrafiltration process for viral reduction.8

The Millipore Viresolve NFP is a normal-flow parvovirus-removal filter with a patented membrane structure for strength and high flow. The NFP filter contains three layers of a highly asymmetric membrane as shown in Figure 1. The filter retains ≥4 logarithmic reduction value (LRV) of 20 nm diameter parvoviridae with high flows (75-150 L/m2/h at differential pressure of 30 psi [2.1 bar]) and high capacities (100-200 L per 0.5 m2 area filter). Features of the filter are listed in Table 1.

Table 1: Features of Viresolve NFP Filter


The development of a parvovirus filter process requires examining how the design variables (for example, feedstock and operating conditions) affect the performance parameters (for example, sizing, product recovery, and LRV). Filter sizing is determined by capacity and flux. Capacity can be conveniently characterized by the



model, based on the gradual plugging of filter pores.


When the volume of a batch is fixed at



and the allowable time to process a batch is fixed at



, the required area will be described by Equation (1).

When the stream is relatively non-fouling and the batch time is low, the size will primarily be determined by the initial flux, J0. With longer batch times and dirtier streams, Vmax determines the size. The concept is easier to grasp by using the sizing index α, a dimensionless term shown in Equation (2) that indicates whether membrane area requirements will primarily be determined by membrane flux or membrane capacity.

The sizing equation can be simplified to Equation (3) when using the sizing index.


The sizing index provides a simple indication of the factors that determine membrane area requirements for a process. When α is greater than 10, the process is flux-limited — more than 90% of the area required is determined by the initial flux. When the value of α is less than 0.1, the process is capacity-limited — more than 90% of the area required is determined by the capacity.

As shown in Figure 2, filters with low α (Filter A) outperform filters with high α (Filter B) at short process times. This allows NFP filters to offer manufacturing flexibility, such as operating in series with other process steps. Most small virus filters on the market have low flux and high capacity and therefore have high α values. These filters are only economical at extended process times.

Figure 2. Comparison of Types of Virus Filters. Sample Calculation: Filter A at 1.0 h. a = 1,000/15 = 66.7 (A/Vb) = (66.7 +1)/1000 = 0.0676. For 100 L will plot 6.76


Increasing pressure can improve filtration throughput, which is why 50 psig (3.5 bar) is usually the optimum operating point. Representative data showing this effect is shown in Figure 3, where using an average flux incorporates the effects of both a high initial flux and a high capacity. NFP devices are rated to 80 psig; most customers prefer not to run above 50.

Figure 3. Pressure Effect on NFP Performance

Protein concentration in the feedstock impacts capacity. Test data in Figure 4 show the effect. This relationship can be modeled as shown in Equation (4).

If a batch with a concentration of C0 and initial volume of V0 is subjected to various levels of dilution to improve the Vmax, the filtration sizing can be determined in terms of the process concentration. Equation (5) is a mass balance.

Plugging this into Equation (3) allows the size to be determined as in Equation (6).

This equation implies the existence of an optimal protein concentration that minimizes virus filter area requirements.10

The optimum concentration is based on the trade off between reduced capacity at higher concentrations and larger batch volumes at lower concentrations. The optimum concentration for most IgG applications is in the range of 6-10 g/L. This relationship is depicted in Figure 5.


Virus filter capacity is affected by plugging aggregates in the feedstock. The nature and quantity of aggregates depends on the protein, its purity and source, buffer conditions, hold time, and temperature. Optimization of buffer conditions, such as pH and ionic strength, can reduce area requirements for NFP filtration. Implementation of the NFP step before a tangential flow filtration (TFF) process with a diafiltration step allows the optimization of the buffer conditions and protein concentration for virus filtration, and any unwanted buffer components can be diafiltered out in the next step. Figure 6 shows how this applies to some IgG applications.

Figure 4. Capacity Dependence on Protein Concentration

Freezing of protein solutions often introduces an aggregate level that impacts NFP capacity, as shown in Figure 7. It is important that fresh solutions be used for process development studies in order to get representative results.

Figure 5. Typical Optimum Protein Concentration for IgG

Heating can also cause aggregation. We created model aggregates by heating IgG at 60°0C for two hours. In tests, these aggregates plugged filters at bulk concentrations below 1.0 mg/L. A monolayer model that assumes that filter capacity is reached once a monolayer of aggregates is formed on the membrane provides a reasonable correlation for this effect.

Figure 6. NFP Capacity: Effects of pH and Conductivity and the Control of Aggregates

Prefilters can be used to remove aggregates and increase the capacity of the virus filter. An NFF (normal flow filter) prefilter composed of cellulose fibers with diatomaceous earth can be used downstream to improve virus filter capacity. This depth filtration technology is widely used in biopharmaceutical processes, removing aggregates and impurities by adsorption. Prefilters can significantly improve NFP capacity. While adsorption will not universally protect a size-exclusion based filter, Table 2 shows this prefiltration effect in a number of buffer systems, demonstrating its broad range of application.

Another approach to prefiltration is employing a reuseable TFF prefilter. Prototype devices have demonstrated the feasibility of this technology, which can increase NFP capacity by as much as tenfold and can offer overall filtration costs from $0.75 to 2.00 /g.11

Figure 7. Filterability of Fresh and Frozen IgG. These points represent the instantaneous flowrate of the experiment, showing the drop as the filter fouls.

The example detailed in Table 3 shows how optimization of these parameters can provide a much more economical viral reduction process step. Following pressure and concentration optimization, the required filtration area is reduced by over ten-fold when we use prefiltration. Process costs drop from $240/L to $12/L.

Table 2: Prefiltration effect for IgG products


Filtration is a robust technology for viral reduction based on size exclusion. Filter LRV is insensitive to most process conditions; however, it has been reported that normal flow virus filters show a decline in LRV with volume processed.


Table 3: Optimization of Viresolve NFP Processing

Figure 8 shows this effect for the Viresolve NFP filter.14 When operating at a low pH, in which the protein is more stable, the flowrate does not decline as rapidly and the LRV is maintained at higher volumetric throughputs.

Bacteriophages are commonly used to characterize the viral retention properties of membrane filters. Millipore has used ΦX-174, a 28 nm bacteriophage, as a small virus surrogate, and it has been shown to be a good model for mammalian virus retention.15

Figure 8. Mammalian Virus LRV for Plasma Protein Processing.14

A model plugging agent, 2,000 kDa Blue Dextran, has been used to demonstrate LRV decline with bacteriophage ΦX-174. Varying concentration of Blue Dextran gives 4 LRV endpoints over a throughput range from 10 to 100 L/m2. When this data is correlated to flow decay, the 4 LRV endpoints are all at roughly 80% flow decay. Figure 9 depicts these trends in the LRV data.

This LRV decline with flow decay is not due to virus adsorption, as in chromatography. If it were, the virus breakthrough due to saturation of adsorption sites would not coincide with the flowrate decline. One possible explanation of these data involves changing pore size distribution. The flow decay of the virus filter is due to the plugging of small pores in the distribution. As these small pores plug, there is increased flow through the larger pores in the distribution. Since larger pores are less retentive of virus, the filter's LRV may decline.

Figure 9. LRV Decline as a Function of Throughput and Flow Decay

Virus validation studies require the demonstration of viral reduction in a scaledown process at a contract facility. In order to validate the desired process throughputs, it is often necessary to minimize the amount of viral spike that is added. Adding 5% virus is typically not needed to demonstrate 4 LRV. With typical titers in contract labs, 0.2 to 1% virus is often enough to reduce the impact on filterability as well as achieve the target LRV. Millipore has published a more detailed protocol to assist in designing these studies.16

Figure 10. Scale-up Studies with Viresolve NFP (Disks refers to small scale testing, 0.00138 m2, capsules are large area testing; 0.08 m2 for 4 in. capsule, 0.5m2 for 10 in capsule)


Other critical considerations in selecting a filter for biopharmaceutical processes are that the filter provides a high yield and that the production process can be scaled up from the small scale test results. Studies were performed using IgG and bovine serum albumin (BSA) to document these properties on Viresolve NFP.


In all cases, the product yield was 98% or higher. Performance scaleability was shown from 47 mm disks to either 4 or 10 in. capsules. This represents scaling factors of 56 for the 4 in. capsule and 350 for the 10 in. capsule. The data are presented in Figure 10. For both data sets the small-scale results are within 15% of the capsule studies and tend to be conservative, which results in a safety factor.

Symbols and Acronyms


Millipore Corporation

- John Cyganowski, Rene Ruede, Vin Pizzi, George Adams, Hong An, John Puglia, Rabia Ballica, Jason Cormier, Susan Barrett, Serene Forte, Natsumi Nagasaki, Yasuhiko Kurisu, Toya Saeki.

Bayer Corporation - Wytold Lebing, Stuart McNull, Joanne Hotta, Katherine Remington


1. Patrick R. Market Research Bureau, Personal communication, Orange, CT. 2002.

2. Republic of Ireland: Government to Pay for Irish Hepatitis C Scandal, Lancet 1997a. 1997 May 17; 349(63).

3. USA: Makers of Blood Products Settle US HIV Lawsuits, Lancet 1997b. 1997 May 17; 349(63).

4. FDA. Draft Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. Bethesda, MD; 1994.

5. ICH. Viral Safety Evaluation of Biotechnology Products. Q5A. Geneva, Switzerland; ICH;1996.

6. EMEA. Workshop on viral safety of plasma-derived medicinal products with particular focus on non-enveloped viruses, European Medicines Agency. London, UK; Sept 2000.

7. Levy R, Phillips M, Lutz H. In "Filtration in the Biopharmaceutical Industry." Meltzer T. and Jornitz M. eds. Chapter 20. Marcel Dekker, NY; 1998.

8. FDA. T92-41. Factor IX Products Approved for Hemophilia B. 1992.

9. Badmington F, Wilkins R, Payne M, and Honig E. Pharm. Tech. Sept, 1995:p. 64-76.

10. Lutz, H. US Patent 5,597,486. Membrane Filtration with Optimized Addition of Second Liquid to Maximize Flux. 1997 Jan 28.

11. Siwak M, Kosugi K, Ono K, An H, Puglia J, Production Technology Department, Benesis Corporation. Virus Filtration Performance: The Impact of Aggregate Removal from Plasma Derived Human IV IgG by a UF Membrane Process. IBC Biopharmaceutical Production Week. 2001.

12. Hirasaki T, Noda T, Nakano H, Ishizaki Y, Manabe S, and Yamamoto N. Polym. J. 1994; 26:1244-1256.

13. Omar A, and Kempf C. Transfusion. 2002; 42:1005-1010.

14. Hotta J., et al. Planova Workshop, Washington, DC, 2002.

15. DiLeo AJ, Vacante DA, Deane EF, Biologicals. 1993; 21:275-286.

16. Millipore Application Note, Ensuring Regulatory Compliance: Validation of Virus Filtration, AN1650EN00, Bedford MA. 2002.

17. Millipore Technical Brief, ViresolveAE NFP Filters Predictably Scale, T±020EN00, Bedford MA. 2002.